NewsBite

Exclusive

Atomo Diagnostics pushes ahead with IPO, boosted by COVID-19 prospects

Atomo, backed by billionaire developer Lang Walker, is working with several manufacturing customers to develop a rapid blood self-test for COVID-19.

Carrie LaFrenz
Carrie LaFrenzSenior reporter

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Despite market turmoil, Atomo Diagnostics – the biotech backed by billionaire developer Lang Walker and former Macquarie bank boss Allan Moss – is pushing head with its planned ASX float after receiving increased interest on the back of the conronavirus pandemic.

Late last week its broker, Canaccord Genuity, mulled pulling the initial public offer but in light of the heightened interest from four diagnostic companies in China, Europe and the United States about its self-testing blood kits for coronavirus, Atomo is still seeking to raise $30 million at 20¢ a share.

Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Healthcare & fitness

Fetching latest articles

Most Viewed In Companies

    Original URL: https://www.afr.com/companies/healthcare-and-fitness/atomo-diagnostics-pushes-ahead-with-ipo-boosted-by-covid-19-prospects-20200317-p54az9